Brief Report: Should Abacavir Be a First-Line Alternative for Adults with HIV in Sub-Saharan Africa?

Guinevere Q. Lee; Suzanne McCluskey; Yap Boum; Peter W. Hunt; Jeffrey N. Martin; David R. Bangsberg; Xiaojiang Gao; P. Richard Harrigan; Jessica E. Haberer; Mark J. Siedner

doi:10.1097/QAI.0000000000001487

Brief Report: Should Abacavir Be a First-Line Alternative for Adults with HIV in Sub-Saharan Africa?

Guinevere Q. Lee, Suzanne McCluskey, Yap Boum, Peter W. Hunt, Jeffrey N. Martin, David R. Bangsberg, Xiaojiang Gao, P. Richard Harrigan, Jessica E. Haberer, Mark J. Siedner

School Of Public Health

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Despite a poor toxicity profile, zidovudine supersedes abacavir (ABC) as an alternative first-line agent in most international treatment guidelines because of concerns about HLA-B57:01-related ABC-hypersensitivity. We detected one case of HLA-B57:01 carriage among 513 HIV-infected individuals in Uganda, which, in combination with previous reports, supports the safety of ABC in the region.

Original language	English (US)
Pages (from-to)	188-192
Number of pages	5
Journal	Journal of Acquired Immune Deficiency Syndromes
Volume	76
Issue number	2
DOIs	https://doi.org/10.1097/QAI.0000000000001487
State	Published - Oct 1 2017

Keywords

Africa
HIV
HLA-B57:01
Uganda
abacavir
antiretroviral therapy

ASJC Scopus subject areas

Infectious Diseases
Pharmacology (medical)

Access to Document

10.1097/QAI.0000000000001487

Cite this

@article{9fc8f587106449a6b5d9555861678165,

title = "Brief Report: Should Abacavir Be a First-Line Alternative for Adults with HIV in Sub-Saharan Africa?",

abstract = "Despite a poor toxicity profile, zidovudine supersedes abacavir (ABC) as an alternative first-line agent in most international treatment guidelines because of concerns about HLA-B57:01-related ABC-hypersensitivity. We detected one case of HLA-B57:01 carriage among 513 HIV-infected individuals in Uganda, which, in combination with previous reports, supports the safety of ABC in the region.",

keywords = "Africa, HIV, HLA-B57:01, Uganda, abacavir, antiretroviral therapy",

author = "Lee, {Guinevere Q.} and Suzanne McCluskey and Yap Boum and Hunt, {Peter W.} and Martin, {Jeffrey N.} and Bangsberg, {David R.} and Xiaojiang Gao and Harrigan, {P. Richard} and Haberer, {Jessica E.} and Siedner, {Mark J.}",

year = "2017",

month = oct,

day = "1",

doi = "10.1097/QAI.0000000000001487",

language = "English (US)",

volume = "76",

pages = "188--192",

journal = "Journal of Acquired Immune Deficiency Syndromes",

issn = "1525-4135",

publisher = "Lippincott Williams and Wilkins",

number = "2",

}

TY - JOUR

T1 - Brief Report

T2 - Should Abacavir Be a First-Line Alternative for Adults with HIV in Sub-Saharan Africa?

AU - Lee, Guinevere Q.

AU - McCluskey, Suzanne

AU - Boum, Yap

AU - Hunt, Peter W.

AU - Martin, Jeffrey N.

AU - Bangsberg, David R.

AU - Gao, Xiaojiang

AU - Harrigan, P. Richard

AU - Haberer, Jessica E.

AU - Siedner, Mark J.

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Despite a poor toxicity profile, zidovudine supersedes abacavir (ABC) as an alternative first-line agent in most international treatment guidelines because of concerns about HLA-B57:01-related ABC-hypersensitivity. We detected one case of HLA-B57:01 carriage among 513 HIV-infected individuals in Uganda, which, in combination with previous reports, supports the safety of ABC in the region.

AB - Despite a poor toxicity profile, zidovudine supersedes abacavir (ABC) as an alternative first-line agent in most international treatment guidelines because of concerns about HLA-B57:01-related ABC-hypersensitivity. We detected one case of HLA-B57:01 carriage among 513 HIV-infected individuals in Uganda, which, in combination with previous reports, supports the safety of ABC in the region.

KW - Africa

KW - HIV

KW - HLA-B57:01

KW - Uganda

KW - abacavir

KW - antiretroviral therapy

UR - http://www.scopus.com/inward/record.url?scp=85021134362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021134362&partnerID=8YFLogxK

U2 - 10.1097/QAI.0000000000001487

DO - 10.1097/QAI.0000000000001487

M3 - Article

C2 - 28639996

AN - SCOPUS:85021134362

SN - 1525-4135

VL - 76

SP - 188

EP - 192

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

IS - 2

ER -

Brief Report: Should Abacavir Be a First-Line Alternative for Adults with HIV in Sub-Saharan Africa?

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this